CRA Insights

The Supreme Court of Canada hears the GlaxoSmithKline transfer pricing case

February 15, 2012

After more than 15 years, the battle between the Canada Revenue Agency and Glaxo Canada over the transfer price for ranitidine—the active pharmaceutical ingredient used to make the branded, anti-ulcer drug Zantac—finally reached the Supreme Court of Canada (SCC) last month.

Related capabilities